Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2014; 20(26): 8482-8490
Published online Jul 14, 2014. doi: 10.3748/wjg.v20.i26.8482
Published online Jul 14, 2014. doi: 10.3748/wjg.v20.i26.8482
hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
Stina Nordh, Daniel Ansari, Roland Andersson, Department of Surgery, Clinical Sciences Lund, Lund University and Skåne University Hospital, SE-221 85 Lund, Sweden
Author contributions: Nordh S performed the literature search; Nordh S and Ansari D were involved in data analysis and manuscript writing; Andersson R designed the study and revised the manuscript; all authors read and approved the final manuscript.
Correspondence to: Roland Andersson, MD, PhD, Department of Surgery, Clinical Sciences Lund, Lund University and Skåne University Hospital, Paradisgatan 2, SE-221 85 Lund, Sweden. roland.andersson@med.lu.se
Telephone: +46-46-172359
Received: October 8, 2013
Revised: March 3, 2014
Accepted: March 12, 2014
Published online: July 14, 2014
Processing time: 279 Days and 3.3 Hours
Revised: March 3, 2014
Accepted: March 12, 2014
Published online: July 14, 2014
Processing time: 279 Days and 3.3 Hours
Core Tip
Core tip: Human equilibrative nucleoside transporter 1 is a predictive marker for pancreatic cancer patients treated with gemcitabine.